Danib100 mg

Danib is a tyrosine kinase inhibitor (TKI) approved for the treatment of certain Philadelphia chromosome-positive (Ph+) leukemias. Its use is classified by strength of evidence as follows:

FDA-approved / established indications

• Newly diagnosed adults with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase.
• Adults with chronic, accelerated, or myeloid/lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy, including imatinib.
• Adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.
• Pediatric patients 1 year of age and older with Ph+ CML in chronic phase (newly diagnosed, or resistant/intolerant to prior TKI therapy).
• Pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL, used in combination with chemotherapy (combination-therapy-dependent indication).

Off-label / investigational use

Danib is sometimes used off-label in other BCR-ABL-driven or SRC-kinase-driven conditions under specialist oncology guidance; such use is not FDA-approved and should only occur within a clinical trial or specialist protocol.

Each film-coated tablet contains Dasatinib (as the monohydrate) in strengths typically ranging from 20 mg to 140 mg, along with standard pharmaceutical excipients used in tablet coating and formulation.

Danib is an orally administered, second-generation small-molecule tyrosine kinase inhibitor used in the treatment of Philadelphia chromosome-positive leukemias. It is supplied as film-coated tablets and is taken once or twice daily depending on the indication.

Danib belongs to the therapeutic class of antineoplastic agents – tyrosine kinase inhibitors (BCR-ABL inhibitors), a category of targeted cancer therapy.

Mechanism

Dasatinib is a multi-targeted kinase inhibitor that binds to and inhibits the BCR-ABL fusion tyrosine kinase (the driver of Philadelphia chromosome-positive leukemias) in multiple conformations, including both active and inactive forms of the kinase domain. This broader binding profile allows it to remain active against many BCR-ABL mutations that confer resistance to first-generation TKIs such as imatinib. Dasatinib also inhibits SRC-family kinases, c-KIT, PDGFR-β, and ephrin (EPH) receptor kinases.

Pharmacokinetics

• Absorption: Rapidly absorbed after oral administration; peak plasma concentration reached in 0.5–6 hours; food has minimal effect on overall exposure.
• Distribution: Approximately 96% bound to plasma proteins; large apparent volume of distribution indicating extensive extravascular distribution.
• Metabolism: Extensively metabolized in the liver, predominantly via CYP3A4.
• Elimination half-life: Approximately 3–5 hours.
• Excretion: Primarily via feces, with a smaller fraction excreted in urine.

Danib tablets should be swallowed whole with a glass of water, with or without food, at approximately the same time each day. Do not crush, split, or chew the tablets.

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir): significantly increase Danib plasma levels, raising toxicity risk — concurrent use should generally be avoided; if unavoidable, dose reduction and close monitoring are needed.
• Strong CYP3A4 inducers (e.g., rifampin, phenytoin, carbamazepine, St. John's Wort): significantly decrease Danib levels, risking loss of efficacy — avoid concurrent use where possible.
• Acid-reducing agents: Proton pump inhibitors substantially reduce Danib absorption by raising gastric pH and should be avoided; if an antacid or H2-receptor blocker is required, it should be separated from Danib dosing by several hours.
• QT-prolonging drugs (e.g., certain antiarrhythmics, antipsychotics, some antibiotics): additive risk of QT prolongation when combined with Danib — avoid concurrent use where possible and monitor ECG if combination is necessary.
• Narrow-therapeutic-index CYP3A4 substrates (e.g., cyclosporine, sirolimus, certain ergot derivatives): Danib may raise their plasma levels — use with caution and monitor.

Common side effects

• Myelosuppression: thrombocytopenia, neutropenia, anemia (see Precautions and Warnings)
• Fluid retention: peripheral edema, pleural effusion
• Diarrhea, nausea, vomiting
• Headache, fatigue
• Musculoskeletal pain, rash
• Bleeding events (mostly mild, e.g., epistaxis, bruising)

Serious/less common side effects

• Severe hemorrhage (including gastrointestinal or central nervous system bleeding)
• QT-interval prolongation and cardiac arrhythmia
• Pulmonary arterial hypertension (potentially irreversible) and pulmonary edema
• Congestive heart failure/cardiac dysfunction
• Growth retardation in pediatric patients with long-term use
• Tumor lysis syndrome (in patients with high tumor burden)

Danib can cause fetal harm based on animal reproduction studies and its mechanism of action; it should be avoided during pregnancy. Danib should be used only if clearly needed and the potential benefit justifies the potential risk to the fetus, and only under close specialist supervision. Females of reproductive potential should use effective contraception during treatment with Danib and for at least 30 days after the final dose; male patients with partners of reproductive potential should also use effective contraception. Breastfeeding should be avoided during treatment with Danib and for at least 2 weeks after the last dose, due to the potential for serious adverse effects in a nursing infant. A physician must be consulted before use in pregnancy or lactation.

Boxed warnings

Danib carries boxed warnings for the following serious risks, which require regular monitoring:

• Myelosuppression: severe thrombocytopenia, neutropenia, and anemia — obtain complete blood counts (CBC) weekly for the first 2 months, then periodically.
• Fluid retention: including pleural effusion, pericardial effusion, and pulmonary edema — monitor for unexplained weight gain, dyspnea, or swelling.
• Cardiovascular events: including cardiac dysfunction and vascular events.
• Gastrointestinal bleeding: use caution with concurrent antiplatelet or anticoagulant therapy.
• QT-interval prolongation: correct electrolyte abnormalities before starting; use caution with other QT-prolonging drugs (see Interactions).
• Pulmonary arterial hypertension (PAH): may occur at any time during treatment and may be irreversible; evaluate patients for signs/symptoms of underlying cardiopulmonary disease before and during treatment.

Other precautions

• Do not crush or break tablets; if a tablet is accidentally broken, avoid direct contact with the powder due to potential embryo-fetal risk to caregivers who are or may become pregnant.
• Monitor growth and development in pediatric patients receiving long-term therapy.
• Use with caution in patients with a history of, or risk factors for, cardiac disease.

Overdose with Danib may worsen myelosuppression, bleeding risk, fluid retention, and cardiac effects such as QT prolongation. There is no specific antidote. If overdose is suspected, seek immediate medical attention or contact emergency services/a poison control center; management is supportive, with close monitoring of blood counts and cardiac status in a medical facility. Do not attempt home treatment for a suspected overdose.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric use

Danib is approved for use in pediatric patients 1 year of age and older for the indications described under Indications; safety and efficacy in children younger than 1 year have not been established. Growth and bone development should be monitored during long-term therapy.

Elderly

No overall differences in safety or effectiveness have been observed between elderly and younger adult patients, but greater sensitivity to adverse effects (particularly fluid retention) cannot be ruled out; monitor closely.

Renal impairment

Data are limited; use with caution and physician-directed monitoring.

Hepatic impairment

Use with caution, as hepatic metabolism of Danib may be affected; individualized dosing under specialist supervision is advised.

Treatment with Danib for chronic myeloid leukemia and Ph+ ALL is typically continued long-term (often indefinitely) until disease progression, unacceptable toxicity, or a physician-directed change in therapy occurs. In select patients with a sustained deep molecular response, a physician may consider a carefully monitored treatment-free remission attempt; this decision must only be made by the treating hematologist/oncologist.

Antineoplastic agent; tyrosine kinase inhibitor (TKI); BCR-ABL inhibitor; targeted (precision) cancer therapy.

Dasatinib works by binding to and inhibiting the abnormal BCR-ABL tyrosine kinase enzyme produced by the Philadelphia chromosome translocation, which drives uncontrolled proliferation of leukemic cells. By blocking this and related kinases (SRC-family kinases, c-KIT, PDGFR-β), Dasatinib suppresses the growth signal that sustains Philadelphia chromosome-positive leukemia cells, including many that have become resistant to earlier tyrosine kinase inhibitors.

D

Danib is approved for pediatric patients 1 year of age and older with Ph+ CML in chronic phase, and for newly diagnosed pediatric Ph+ ALL in combination with chemotherapy. Dosing is weight-based and must be individualized by a pediatric oncology specialist. Safety and efficacy have not been established in children under 1 year of age. Long-term monitoring of growth and bone development is recommended.